Autolus Therapeutics plc ADR (AUTL) concluded trading on Thursday at a closing price of $1.35, with 5.46 million shares of worth about $7.37 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -59.58% during that period and on May 08, 2025 the price saw a gain of about 9.76%. Currently the company’s common shares owned by public are about 266.13M shares, out of which, 240.32M shares are available for trading.
Stock saw a price change of 0.00% in past 5 days and over the past one month there was a price change of 14.41%. Year-to-date (YTD), AUTL shares are showing a performance of -42.55% which decreased to -66.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.11 but also hit the highest price of $5.00 during that period. The average intraday trading volume for Autolus Therapeutics plc ADR shares is 1.70 million. The stock is currently trading -0.74% below its 20-day simple moving average (SMA20), while that difference is down -13.78% for SMA50 and it goes to -52.64% lower than SMA200.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) currently have 266.13M outstanding shares and institutions hold larger chunk of about 53.88% of that.
The stock has a current market capitalization of $359.26M and its 3Y-monthly beta is at 1.69. It has posted earnings per share of -$0.87 in the same period. It has Quick Ratio of 10.77 while making debt-to-equity ratio of 0.70. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AUTL, volatility over the week remained 9.62% while standing at 11.13% over the month.
Stock’s fiscal year EPS is expected to drop by -4.27% while it is estimated to increase by 20.27% in next year. EPS is likely to grow at an annualized rate of 21.60% for next 5-years, compared to annual growth of 21.36% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on November 18, 2024 offering a Buy rating for the stock and assigned a target price range of between $7 and $7.60 to it. Coverage by Redburn Atlantic stated Autolus Therapeutics plc ADR (AUTL) stock as a Buy in their note to investors on November 15, 2024, suggesting a price target of $13 for the stock. On November 09, 2023, Deutsche Bank Initiated their recommendations, while on March 27, 2023, Wells Fargo Resumed their ratings for the stock with a price target of $8. Stock get a Buy rating from Bryan Garnier on March 17, 2023.
